Plasma indices of endothelial and platelet activation in Rheumatoid Disease: Relationship to cardiovascular co-morbidity

International Journal of Cardiology

Volumn 134, Issue 1, 2009, Pages 97-103

  Bhatia, Gurbir S ^a   Sosin, Michael D ^a   Patel, Jeetesh V ^a   Grindulis, Karl A ^b   Khattak, Fazal H ^b   Davis, Russell C ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Cardiovascular risk; E selectin; Endothelium; P selectin; Rheumatoid; von Willebrand factor

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; PADGEM PROTEIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MARKER; ENDOTHELIUM; ENDOTHELIUM LESION; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE SYSTOLIC DYSFUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATIC DISEASE; THROMBOCYTE ACTIVATION;

AGED; BIOLOGICAL MARKERS; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; P-SELECTIN; PLATELET ACTIVATION; RHEUMATIC DISEASES; RISK FACTORS; VON WILLEBRAND FACTOR;

EID: 64149123532     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.01.038     Document Type: Article

References (28)

1. Sattar N., McCarey D.W., Capell H., and McInnes I.B. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108 (2003) 2957-2963
2. Bhatia G.S., Sosin M.D., Khattak F., Davis R.C., and Lip G.Y. Rheumatoid Disease and ischaemic heart disease: insights from pathophysiology and vascular biology. Int J Cardiol 105 (2005) 1-10
3. Lip G.Y., and Blann A.D. Thrombogenesis, atherogenesis and angiogenesis in vascular disease: a new 'vascular triad'. Ann Med 36 (2004) 119-125
4. Wallberg-Jonsson S., Cederfelt M., and Rantapaa-Dahlqvist S. Haemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year follow up study. J Rheumatol 27 (2000) 71-75
5. Prevoo M.L.L., van't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B.A., and van Riel P.L.C.M. Modified disease activity scores that include twenty-eight-joints counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995) 44-48
6. Spencer C.G.C., Gurnry D., Blann A.D., Beevers D.G., and Lip G.Y. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension. A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 40 (2002) 61-66
7. Conlon M.G., Folsom A.R., Finch A., et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 70 (1993) 380-385
8. Folsom A.R., Wu K.K., Shahar E., and Davis C.E. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Arterioscler Thromb 13 (1993) 1829-1836
9. Lip G.Y., Lowe G.D., Metcalfe M.D., Rumley A., and Dunn F.G. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 76 (1995) 453-458
10. Gibbs C.R., Blann A.D., Watson R.D., and Lip G.Y. Abnormalities of hemorrheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 103 (2001) 1746-1751
11. Lau C.S., McLaren M., Hanslip J., Kerr M., and Belch J.J.F. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis. Ann Rheum Dis 5 (1993) 643-649
12. Voskuyl A.E., Hazes J.M., Zwinderman A.H., et al. Diagnostic strategy for the assessment of rheumatoid vasculitis. Ann Rheum Dis 62 (2003) 407-413
13. Daza L., Aguirre M., Jimenez M., Herrera R., and Bollain J.J. Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors. Clin Rheumatol 26 (2007) 533-537
14. Wallberg-Jonsson S., Backman C., Johnson O., et al. Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 28 (2001) 2597-2602
15. Pottinger B.E., Read R.C., Paleolog E.G., Higgins P.G., and Pearson J.D. Von Willebrand factor is an acute phase reactant in man. Thromb Res 53 (1989) 387-394
16. Pham T., Gossec L., Constantin A., et al. Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 73 (2006) 379-387
17. Wallberg-Jonsson S., Johansson H., Ohman M.L., and Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 26 (1999) 2562-2571
18. Jilma B., Fasching P., and Ruthner C. Elevated circulating P-selectin in insulin dependent diabetes mellitus. Thromb Haemost 76 (1996) 328-332
19. Parker III C., Vita J.A., and Freedman J.E. Soluble adhesion molecules and unstable coronary artery disease. Atherosclerosis 156 (2001) 417-424
20. Chin B.S., Gibbs C.R., Blann A.D., and Lip G.Y. Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for beta-blocker selection. Clin Sci (Lond) 105 (2003) 507-512
21. Littler A.J., Buckley C.D., Wordsworth P., Collins I., Martinson J., and Simmons D.L. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol 36 (1997) 164-169
22. Ertenli I., Kiraz S., Arici M., Haznaredoglu I.C., Calguneri M., Celik I., and Kirazli S. P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis. J Rheumatol 25 (1998) 1054-1058
23. Blann A.D., Herrick A., and Jayson M.I. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 34 (1995) 814-819
24. Cobankara V., Ozatli D., Kiraz S., et al. Successful treatment of rheumatoid arthritis is associated with a reduction in serum sE-selectin and thrombomodulin level. Clin Rheumatol 23 (2004) 430-434
25. Kuuliala A., Eberhardt K., Takala A., Kautianen H., Repo H., and Leirisalo-Repo M. Circulating soluble E-selectin in early rheumatoid arthritis: a prospective five year study. Ann Rheum Dis 61 (2002) 242-246
26. Steiner M., Reinhardt K.M., Krammer B., Ernst B., and Blann A.D. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 72 (1994) 979-984
27. Chong A.Y., Blann A.D., Patel J., Freestone B., Hughes E., and Lip G.Y. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 110 (2004) 1794-1798
28. Hobbs F.D., Roalfe A.K., Davis R.C., Davies M.K., and Hare R. Midlands Research Practices Consortium (MidReC). Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 28 9 (2007) 1128-1134